Last reviewed · How we verify

Propofol as induction agent

Fayoum University Hospital · FDA-approved active Small molecule

Propofol is a rapid-acting intravenous sedative-hypnotic that enhances inhibitory GABA neurotransmission in the central nervous system to induce unconsciousness.

Propofol is a rapid-acting intravenous sedative-hypnotic that enhances inhibitory GABA neurotransmission in the central nervous system to induce unconsciousness. Used for Induction of general anesthesia in adults and children, Sedation during mechanical ventilation in intensive care settings, Sedation for diagnostic and therapeutic procedures.

At a glance

Generic namePropofol as induction agent
SponsorFayoum University Hospital
Drug classIntravenous sedative-hypnotic
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and neuronal hyperpolarization. This results in rapid onset of sedation and unconsciousness suitable for anesthesia induction. The drug has a short duration of action due to rapid redistribution and metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: